Reading this on a mobile device? Try our optimized mobile version here:

February 19, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Chiasma licenses acromegaly drug candidate Octreolin to Roche
    Chiasma granted Roche Holding exclusive worldwide rights to develop and market its experimental growth hormone disorder drug Octreolin, an oral form of the somatostatin analogue ocreotide, first as a treatment for acromegaly and later for neuroendocrine tumors. Roche unit Genentech will sell the product in the U.S. if it is approved by the FDA. Chiasma will get $65 million upfront and as much as $530 million in milestones payments plus sales royalties. PharmaTimes (U.K.) (2/18), Fox Business/Dow Jones Newswires (2/18) LinkedInFacebookTwitterEmail this Story
Enterprise Integration
Harness the Full Value of an Enterprise Quality Management System by Integrating with Other Enterprise Applications to increase Organizational Efficiency and Effectiveness—Without Unnecessary Customizations. View Video Now.
  Health Care & Policy 
  • FDA gives Dako nod on rapid cancer diagnostic test
    Dako has received approval from the FDA to market its HER2 IQFISH pharmDx test, which is used to cut the turnaround time for cancer diagnosis from the industry standard of two days to three-and-a-half hours. The test, which identifies the HER2 gene in breast cancer diagnosis, is the first FDA-approved test that works with Dako's IQISH system, the company said. GenomeWeb Daily News (free registration) (2/15) LinkedInFacebookTwitterEmail this Story
  • Phytopharm's Parkinson's drug candidate disappoints in trial
    Phytopharm said its experimental drug Cogane did not outperform a placebo in a 400-patient trial for the treatment of early-stage Parkinson's disease. "Cogane had demonstrated encouraging efficacy in a wide range of industry standard preclinical models but this promise has not translated into clinically meaningful efficacy," CEO Tim Sharpington said. The firm is evaluating its pipeline. Yahoo/Reuters (2/18) LinkedInFacebookTwitterEmail this Story
  • Human Connectome Project prepares to release initial images
    The Human Connectome Project is preparing to release the first collection of images taken by a powerful imaging system as part of an effort to map the human brain. The initial images to be released in the coming weeks come from 80 to 100 people. Researchers hope the five-year project will help improve scientists' understanding of how the brain works as well as the mechanisms involved when something goes awry. The project, which will look at 1,200 brains, will also collect genetic and behavioral information to develop a model of the human psyche. BBC (2/16) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Global Developments 
  Food & Agriculture 
  • AquaBounty confident that biotech salmon will win FDA approval
    AquaBounty Technologies was disappointed by the FDA's decision to extend the public comment period for its biotech salmon, but it believes the delay won't affect its chances for approval. In 2010, an FDA advisory panel found the salmon posed no risk to safety or the environment. "There has been neither new information nor a clear legal or regulatory issue raised by the FDA since that time," AquaBounty CEO Ronald Stotish said. FoodNavigator (2/18) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • BIO, other groups fire back at attempt to undo RFS
    BIO and other biofuel groups are responding to a request by the American Petroleum Institute to eliminate the 2012 cellulosic biofuels requirement under the Renewable Fuel Standard. "API is trying to re-litigate in the press the issues it lost in court. The Court recognized EPA's authority to administer the rules for the RFS, and EPA should reject this attempt to spin that decision," said BIO Industrial and Environmental Section Executive Vice President Brent Erickson. (2/18) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Everything that lives, lives not alone, nor for itself."
--William Blake,
British poet and painter

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information